.png)
In Indian stock markets, the 52-week high and 52-week low are widely tracked indicators by traders, investors, mutual funds, and institutional participants. These levels represent the highest and lowest prices a stock has traded at over the past one year on NSE or BSE.
In 2026, with Indian markets seeing higher retail participation, algorithmic trading, and faster information flow, these levels have become even more important in identifying momentum stocks and potential value opportunities.
But the key question remains:
Should you buy strength at 52-week highs or buy weakness at 52-week lows?
Let’s break both strategies down clearly.
A 52-week high strategy focuses on stocks that are trading at or near their highest price in the last one year. Contrary to traditional belief, strong stocks often continue to rise due to sustained demand.
Stocks hitting 52-week highs often indicate:
In 2026, with FII and DII flows driving momentum, many breakout stocks emerge from 52-week high lists.
Stocks like leading PSU banks, capital goods companies, and select IT names have historically made multiple 52-week highs during long bull phases, rewarding momentum traders.
While momentum can be powerful, it is not risk-free.
Key risks include:
This is why volume confirmation, earnings visibility, and broader market trend analysis are critical.
A 52-week low strategy focuses on stocks trading near their lowest price of the last year. These stocks may be under pressure due to temporary challenges or broader sector weakness.
For long-term investors, such phases can sometimes present value opportunities.
Stocks at 52-week lows may reflect:
In 2026, sectors like metals, chemicals, or mid-cap IT may throw up selective value opportunities when sentiment turns pessimistic.
Not every cheap stock is a good investment.
A value trap occurs when:
Many stocks remain at 52-week lows for years without recovery. This is why fundamental analysis is non-negotiable.
52-week high is momentum-driven
52-week low is value-driven
Highs: Short to medium-term traders
Lows: Long-term investors
Highs: Volatility risk
Lows: Fundamental risk
Highs: Volume, trend, earnings momentum
Lows: Balance sheet, cash flows, recovery potential
There is no single correct answer.
In trending bull markets, 52-week high strategies tend to outperform as capital chases winners.
In volatile or sideways markets, selective 52-week low investing may deliver better long-term returns if backed by strong fundamentals.
Smart investors in 2026 increasingly use a blended approach:
A balanced approach could look like this:
SEBI-regulated brokers and research platforms help investors track such opportunities with structured tools and insights.
Whether you follow highs or lows, success depends on:
At Swastika Investmart, investors benefit from SEBI-registered research, technology-enabled platforms, and continuous investor education to navigate such strategies responsibly.
It can be risky if done without confirmation. Stocks with strong earnings momentum and volume support often continue trending higher.
No. Some stocks are at 52-week lows due to permanent business issues, making them value traps.
Beginners should focus on understanding fundamentals and risk management before using either strategy aggressively.
Yes, if the company has strong growth visibility and sustainable earnings, long-term investors can hold momentum stocks as well.
In 2026, both 52-week high and 52-week low strategies remain relevant in Indian markets. The real edge comes not from choosing one over the other, but from applying research, patience, and discipline.
If you’re looking to build a structured approach with expert-backed insights, Swastika Investmart offers a trusted ecosystem with research support, advanced tools, and investor-first guidance.
A new variant of COVID 19 has been identified which was named Omicron by the World Health Organization (WHO). Many share trading analysts suggested that this new variant tends to spread quicker than the Delta variant and is much more infectious than other COVID variants.
Also, they said that the vaccines available now are less effective against this new variant. As we are trying to recover from the second wave, this omicron variant caused precariousness in the market.
If we talk about the current week, then we will get to know that the GDP for the July-Sept quarter of FY 2022 showed a total growth of 8.4%, which is the fourth consecutive quarter of positive growth post the major contraction.
If India wants to remain in the position of the fastest-growing economy in the year 2023, all restrictions are lifted and the growth continues to rise.
As said above, if the new strain emerges again, the government will take the necessary steps to bring back the restrictions.
Recently the government has announced that it will invest Rs 257 Billion into the electric vehicle initiatives by the year 2025.
The pandemic has acted as a catalyst of a positive change to shape the healthcare sector across the world.
Here are some of the potential stocks you need to pay attention to in India as the new variant of concern spreads.
Its product portfolio contains generics and medications in key helpful fragments.
In India, Cipla is one of the biggest pharma organizations and the biggest Indian exporter to developing business sectors.
During the pandemic, Cipla carried out 7 products as a piece of their Covid-19 portfolio. These incorporate medications, sanitisers, and antigen and counter antibody testing kits.
During the sensitive days of the pandemic, it went into various associations to advertise items in oncology, biosimilars, and metabolic illnesses.
Cipla saw a solid 12% year on year (YoY) development in income in the monetary year 2021 predominantly due to respiratory opening in the US and their Covid portfolio.
During a similar period, Cipla's (EBITDA) margin grew by more than 350 basis points to 22.5% from 18.9%. Lower expenses because of cost enhancement drives and lower on-ground activities because of lockdown prompted extension in margins.
The organization's net overall revenue remained at a notable high of 12.6% in FY 2021 against 9% in the monetary year 2020. Operational efficiency and lower finance costs because of prepayment of debt have prompted higher net margins
During the year, the company launched 9 abbreviated new drug applications (ANDA), filed for 8 ANDAs out of which it has received approval for the 7 ANDAs.
Alkem Laboratories is a multinational pharmaceutical company that primarily manufactures and sells pharmaceutical generics, nutraceuticals, in India and globally.
As per the sources, Alkem is considered the fifth largest Indian pharmaceutical company in terms of market share. As of now, the company has manufactured 20 facilities and 6 R&D facilities in India and US.
The company has more than 800 brands out of which 12 brands have annual sales of more than Rs 1 billion.
During the pandemic, the company’s operations were little affected. However, it saw a full recovery during the whole phase.
In 2021, the company’s total revenue grew up to 6.2% in FY 2021, which was 13.4% in the previous year.
Furthermore, the company has also experienced a drop in sales, which might affect the company’s growth. However, the company managed to recover as the sales growth was primarily supported by their international business.
The EBITDA margin for FY 2021 is 21.9%, which has grown from 17.72% from the last year.
Thyrocare Technologies is an Indian multinational chain of diagnostic and preventive care technologies that are known for offering more than 279 tests and 79 profiles of tests to detect several disorders.
The company has a centralized processing laboratory where it fulfills the requirement of the customers. The company also operates regional processing laboratories in metro cities to ensure speedy processing.
Thyrocare has a network across India as it supports a logistic network and IT infrastructure.
The company further declared a revenue growth of 14% in FY 2021 because of an increase in the diagnostic revenue due to COVID 19 testing.
Dr Lal Pathlabs is an international service provider and one of the top diagnostic chains in India. The company is located in Delhi.
It offers more than 5000 diagnostic tests, related healthcare tests and services across 3,705 centres.
During the lockdown, the company extended its reach digitally and physically to improve its covid testing.
The revenue of Dr Lal path labs grew by 18% in FY 2021 against a 10.6% growth in the financial year 2020.
The EBITDA of the year 2021 was marked at 29.3% as compared to the last year which was 27.5% in the last financial year.
The healthcare industry remains resilient even in the pandemic. However, the companies have also gone through losses but due to the demand for healthcare and antibiotics, these companies have managed to perform better than others.
Other sectors such as FMCGs, and eCommerce companies could also do the same.
The pandemic has completely changed business ethics and the way of doing business.
If you want to invest in good companies, pay attention to those companies that can leverage the changes happening in the economy and push their long term growth terms.
It is suggested to not try to time the market. Instead, invest in the companies that give you better stock market trading returns in the long term.
The SME-IPO boom is still on fire. This year many companies have gone public and many are in the queue. As the year comes to an end, the list of companies going public is not in a mood to take a pause.
Even at the year-end, seven companies claimed to conduct the IPOs in the next 10-15 days, intending to raise more than Rs 19 000 Crore.
The IPO of star health has already come in the first week of December, while the IPOs of the tech companies like Rate Gain Technologies, Anand Rathi Wealth and CE Info Systems will begin in the next week.
The IPOs of Adani Wilmer and Go First Airlines are expected to open for the subscription in the third or fourth week of December.
While the subscription of Tega Industries has already begun and as per the sources, the IPO of the same subscribed 14 times on Day 2.
Adani Wilmer, the maker of Fortune Edible Oil, has already filed DRHP to the stock market regulator organization and the issue is expected to open by December 15. Newly issued shares up to Rs 4500 Crores will be sold by the organization.
The company nearly spends Rs 1900 Crore on the capital investment, Rs 50 Crore on the strategic acquisition and general corporate purposes from the proceeds.
Star health and allied insurance is an Indian health insurance company located in Chennai. The company offer services in a different segment of health such as personal accident, overseas travel insurance, either directly or through other methods like agents, brokers and online.
Rate Gain technologies is a software as a service company that mainly provide services to a wide range of verticles in the travel and hospitality industry.
The services include hotels, airlines, online travel agents, vacation rentals, metasearch companies rail, travel management companies and more.
Also, the organization offers inter-connected products that are equipped for taking revenue creation value chain for their customers by utilizing large information capacities and coordination with other innovation stages to acquire more guests, retain them via personalized guest experiences and seek to maximize their margins.
Anand Rathi is considered India’s leading full-service financial services firm that offers several services such as Wealth Management, Investment Banking, Brokerage and Distribution, Corporate Finance and Advisory and more.
As soon as the IPO of the company has launched, it saw an outstanding response from the investors because the issue was fully subscribed on the first day itself.
The issue received approximately 10 times bids as per the date of NSE. investors bid for 8,29,21,509 equity shares and the total offering was 84,75,000 shares. Initially, the company is selling its shares in the range of Rs 530 - 550.
GO First Airlines is Indian’s first ultra-low-cost airline, headquartered in Mumbai. As of October 2017, the company was the fifth-largest airline in India with a market share of 8.4%.
Go Air began its operations using an Airbus A320 and worked its first departure from Mumbai to Ahmedabad on 4 November 2005.
CE Info Systems aka Mapmyindia is the main service provider of cutting edges digital technologies such as digital maps, geospatial software and location-based IOT technologies in India.
It is a data & technology company offering exclusive digital maps as a service (MaaS), PAAS (Platform as a service) and Software as a Service SAAS.
As per sources, investors of Adani Enterprises, the parent organization of Adani Wilmar, will probably get a 10% decrease in the IPO cost.
CE Info Systems, which possesses MapmyIndia, will dispatch a public offering one week from now to produce generally Rs 1,400 crore.
Promoters and other existing investors, including Qualcomm Asia Pacific, are selling the whole 7.55 million shares on sale.
The organization gives SAAS and stage as help for its digital maps. Its map covers cover 750,000 towns, more than 7,500 towns on a road by-road premise, and 6.3 million kilometers of the road network.
सोने की कीमतों में पिछले सप्ताह दबाव रहा लेकिन कई राज्यों में ओमीक्रॉन वायरस के कारण शुरू हुई सख्ती से इसके भाव सपोर्ट लेते दिखे है। जबकि पिछले सप्ताह में चांदी के भाव में हल्की तेज़ी दर्ज की गई है जो इस सप्ताह के लिए सोने और चांदी के भाव के लिए तेज़ी के संकेत है। क्रिसमस छुट्टियों के कारण सोने और चांदी के भाव अभी सीमित दायरे में बने होने के साथ अस्थिर भी है जिसमे स्थिरता के बाद तेज़ी आ सकती है।
ओमीक्रॉन के मामले अब यूरोप के बाद भारत और अन्य एशिया देशो में बढ़ने लगे है जिसके कारण आर्थिक गतिविधियों में रुकावटें शुरू हो सकती है जो सोने और चांदी में निवेश के लिए सेफ हेवन मांग को बढ़ा सकते है। डॉलर जो सोने के विपरीत दिशा में चलता है, पिछले सप्ताह नरमी रही। अध्ययन से यह भी पता चला है कि ओमाइक्रोन संक्रमण से अस्पताल में भर्ती होने की संभावना कम है, लेकिन यह भी कहा गया है कि इसके संक्रामक होने के कारण गंभीर मामले अभी भी महत्वपूर्ण संख्या में उत्पन्न हो सकते हैं।
नवीनतम कोविड-19 के प्रकोप को रोकने के लिए चीन ने गुरुवार को शीआन शहर को बंद कर दिया ताकि पश्चिमी शहरों में वायरस को फैलने से रोका जा सके। शहर के 130 करोड़ निवासियों को अपने घरों में रहने और ज़रूरतों के लिए हर दूसरे दिन एक व्यक्ति को बाहर जाने के लिए कहा गया है। चीन का यह लॉकडाउन 2020 की शुरुआत की महामारी के बाद से सबसे बड़ा है।
पिछले सप्ताह अमेरिका से जारी होने वाले कोर पीसीई प्राइस इंडेक्स, बेरोज़गारी के दावे और घरो की बिक्री के आकड़ो से कीमती धातुओं को सपोर्ट मिला है। कॉमेक्स वायदा सोना पिछले सप्ताह 6 डॉलर तेज़ होकर 1810 डॉलर प्रति औंस के स्तरों पर पहुंच गया है। कॉमेक्स वायदा चांदी भी 50 सेंट मजबूत होकर 22.90 डॉलर के स्तरों पर रही।
इस सप्ताह सोने और चांदी के भाव सकारात्मक दायरे में रह सकते है। सोने में 47800 रुपये पर सपोर्ट और 49000 रुपये पर प्रतिरोध है। चांदी में 61000 रुपये पर सपोर्ट और 63500 रुपये पर प्रतिरोध है।
RatingSUSBCRIBE Issue OfferIssue Opens onDec 14, 2021Issue Close onDec 16, 2021Total IPO size (cr)588.22Fresh issue (cr)240.00Offer For Sale (cr)348.22Price Band (INR)555-585Market Lot25Face Value (INR)2Retail Allocation35%Listing OnNSE, BSEObjects of the issue ⮚ For Repayment of borrowings ⮚ For Funding working capital requirementIssue Break-up (%)QIB Portion 50NIB Portion 15Retail Portion ⮚ 35Shareholding (No. of Shares)Pre Issue 47,784,086Post Issue 51,886,650Indicative TimetableFinalisation of Basis of Allotment 21-12-2021Refunds/Unblocking ASBA Fund 22-12-2021Credit of equity shares to DP A/c 23-12-2021Trading commences 24-12-2021
Established in 1985, Data Patterns is a defence and aerospace electronics solutions provider specializing in indigenously designed defence equipment. The firm provides equipment for all types of defence and aerospace systems, including space, air, land, and sea.
Electronic hardware design and development, software and firmware design and development, mechanical design and development, product prototype design and development, functional testing and validation, environment testing and verification, and engineering services opportunities are among the company's core competencies.
⮚ It was one of the fastest-growing firms in terms of revenues among significant Indian defence and aerospace companies between Fiscal 2019 and Fiscal 2021, according to the Company Commissioned F&S Report, with a revenue increase of 71%.
⮚ The company's strengths throughout the gamut of defence and aerospace electronics solutions from design to delivery give it a considerable competitive edge in terms of overall development time and cost, as well as competitive pricing when bidding on defence and aerospace contracts.
⮚ The company has design capabilities across the entire spectrum of strategic defence and aerospace electronics solutions including processors, power, radio frequencies (“RF”) and microwave, embedded software and firmware and mechanical engineering.
⮚ The company is upgrading and expanding its facility, with a proposed doubling of available floor area and manufacturing capacity, as well as the addition of large and heavy equipment handling capability, large radar and mobile electronic warfare system integration, and a satellite integration facility. Its testing capabilities are also proposed to be further strengthened.
In the last 3 years, the company has shown strong growth in revenue where it grew at a CAGR of 19% from Rs 132.50 cr to Rs 226.55 cr over the period of FY19 to FY21, during the same period profit has grown at a CAGR of 97% from Rs 7.70 cr in FY19 to Rs 54.6 cr in FY21. The margins of the company are also expanding.
As part of the 'Make in India' initiative, the company will bid on bigger, more challenging contracts. Data Patterns increased its net profitability by approximately 158% between FY20 and FY21.
We believe that the company has enormous potential to grow rapidly thanks to the government's focus on Defense and Aerospace. The IPO is priced at a 49x PE and 13x P/BV to its FY21 earnings at an upper price band of Rs 585. Attractiveness in the defence sector is likely to boost sentiment for the IPO.
DATA PATTERNS (INDIA) LIMITED
⮚ Srinivasagopalan Rangarajan is the Chairman and Managing Director of the Company. He has been associated with the Company since its incorporation. He holds a Bachelor’s Degree of Technology in Chemical Engineering and he has over three decades of experience in business development, corporate affairs, finance and marketing.
⮚ Venkata Subramanian Venkatachalam is the Chief Financial Officer of the Company. He is a fellow member of the Institute of the Chartered Accountants of India. He has over two decades of experience in the finance sector.
⮚ Manvi Bhasin is the Company Secretary and Compliance Officer of the Company. She is an associate of the Institute of the Company Secretaries of India. She has three years of experience in legal and secretarial matters.
⮚ Vijay Ananth K is the Chief Operating Officer and Chief Information Security Officer of the Company. He has more than two decades of experience in software engineering and product management.
⮚ Desinguraja Parthasarathy is the Chief Technical Officer of the Company. He has 32 years of experience in Product Development.
⮚ Thomas Mathuram Susikaran is the Senior Vice President-Business Development. He holds a bachelor’s degree in engineering. He has over 21 years of experience in business development and marketing.
⮚ Nandaki Devi Ramachandracharya is the Deputy General Manager and Management Representative Quality Management System. She has 22 years of experience in test engineering.
⮚ Integrated and strategic defence and aerospace electronics solutions provider based in India, well-positioned to profit from the Make in India initiative.
⮚ Innovation focused business model.
⮚ Sound order book with orders from several prestigious customers in the Indian defence ecosystem. ⮚ The modern certified manufacturing facility of international standards.
⮚ Track record of profitable growth.
⮚ The experienced management team and skilled workforce.
⮚ Continue expansion of product portfolio with complex technology-based products.
⮚ Focus on repeat large volume production orders.
⮚ Improving manufacturing infrastructure and enhancing design and development capabilities
⮚ Augmenting the design and development capabilities and expanding manufacturing infrastructure
⮚ Focus on increasing revenues by leveraging core competencies and growing the services business
⮚ Focus on increasing export business
⮚ The company depends on a limited number of customers for major business.
⮚ Subject to strict quality requirements, customer inspections and audits, and any failure to comply with quality standards may lead to cancellation of existing and future orders
⮚ Failure to qualify for or win bids could have an adverse effect on its business.
⮚ If it does not maintain its technical information and processes discreet, it may lose its competitive advantage.
⮚ The company has significant working capital requirements.
DATA PATTERNS (INDIA) LIMITED
COMPARISON WITH LISTED INDUSTRY PEERS (AS ON 31ST MARCH 2021)
Name of the Company EPS (Basic) NAV P/E Operational Rev (cr) RoNW Data Patterns (India) Ltd 11.89 44.38 49 223.95 26.79% Peer Group MTAR Technologies Ltd 16.99 154.99 83.56 246.43 9.66%Astra Microwave Products Ltd 3.33 64.51 51.28 640.91 5.16%Centum Electronics Ltd 13.31 173.14 34.90 817.43 5.40%Bharat Electronics Ltd 8.62 45.39 23.49 14,108.69 18.99%
FINANCIALS (RESTATED CONSOLIDATED)
Particulars (Rs. In Millions) FY 2021 FY 2020 FY 2019Equity Share Capital 17.00 17.00 17.00Other Equity 2060.70 1517.95 1311.93Net Worth 2077.70 1534.95 1328.93Total Borrowings 332.21 605.66 601.33Revenue from Operations 2239.50 1560.98 1310.63EBITDA 945.88 472.50 269.93Profit Before Tax 745.34 284.29 103.59Net Profit for the year 555.71 210.48 77.02
Issue Opens on Dec 15, 2021Issue Close on Dec 17, 2021 Total IPO size (cr)125.96 Fresh issue (cr) 113.44 Offer For Sale (cr) 12.53 Price Band (INR) 262-274 Market Lot 50 Face Value (INR)10 Retail Allocation 10% Listing On NSE, BSE
⮚ For funding the working capital.
⮚ Capital expenditure for expansion.
QIB Portion 75 NIB Portion 15 Retail Portion 10
Pre Issue1,42,34,947Post Issue1,83,74,947
Finalization of Basis of Allotment 22-12-2021 Refunds/Unblocking ASBA Fund 23-12-2021 The credit of equity shares to DP A/c 24-12-2021 Trading commences 27-12-2021
Registered in 2019, HP Adhesives Limited is an adhesives and sealants company. The company manufactures a wide range of consumer adhesives and sealants such as PVC, cPVC, and uPVC solvent cement, synthetic rubber adhesive, PVA adhesives, silicone sealant, acrylic sealant, gasket shellac, other sealants, and PVC pipe lubricants.
These adhesives and sealant products have applications in multiple industries such as plumbing and sanitary, drainage and water distribution, general-purpose building/ construction, and interior operations as well as for glazing operations, woodwork, footwear, automotive, foam-furnishing, and other varied industries.
⮚ Apart from the above products, the company also sells ancillary products like ball valves, thread seals, and other tapes and FRP products for drainage and architectural solutions.
⮚ The company has grown from a single product to a multi-product adhesives company with sales across India (through a pan-India distribution network) and also in international markets.
⮚ Over the years, Company’s brands “HP” and “Strong Weld” in the PVC adhesives product category have gained increasing acceptance on account of high product quality and efficient pricing.
⮚ The company has a solid business model that focuses on consistently expanding its product portfolio by introducing new product categories and SKUs to cater to a wide range of end-use applications and selling them through its distribution network across India.
⮚ As of September 30, 2021, its distribution network comprised of 4 depots situated in Delhi, Kolkata, Bengaluru, and Indore and more than 750 distributors who cater to more than 50,000 dealers in India
⮚ The company wants to expand its manufacturing capacity at Village Narangi, Raigad, Maharashtra to cater to the growing demand for several product categories.
In the last 3 years, the company has shown stable growth in revenue where it grew from Rs 87.97 cr to Rs 123.87 cr over the period of FY19 to FY21, during the same period profit has grown from Rs 4 cr in FY19 to Rs 10.05 cr in FY21, but the company faced a huge loss of Rs. (4.67) cr in FY20 on the back of exceptional item.
The industry is expected to grow at a CAGR of 6-8% while the company is in a growth phase and is expanding installed capacities for its product lines and is also expanding its portfolio.
The IPO is valued at a PE of 35x and P/BV of 28x to its FY21 earnings. However, if we annualized FY22 earnings PE and P/BV work out to be 81x and 10.38x which is in line with the peer. Due to its small size, the SME-IPO is going to be listed in the T2T segment.
We have an "AVOID" rating for the IPO.
For additional information & risk factors please refer to the Red Herring Prospectus
⮚ Anjana Haresh Motwani, with over 40 years of experience in the adhesive industry, is currently designated as the Executive Director and Chairperson of the Company.
⮚ Karan Haresh Motwani currently holds the position of Managing Director of the Company. He was admitted to the partnership M/s. HP International in 2007.
⮚ Mr Mihir Shah, is the chief financial officer of the Company. He has been associated with the Company since May 2021. He has an overall experience of nearly 15 years in investment banking.
⮚ Ms Jyoti Nikunj Chawda is the Company Secretary & Compliance Officer of the Company. She is a commerce and law graduate from the University of Mumbai and holds an overall experience of nearly 7 years in secretarial and compliance functions.
⮚ Ms Nidhi Haresh Motwani is the Vice President – Operations of the Company, She has been associated with the Company since February 2016. She has an overall experience of 10 years in the fields of branding, marketing, and sales.
⮚ Mr Saurabhraj Bhatt is the Vice President – Sales and Marketing, of the Company. He has an overall experience of about 22 years. He handles the product promotion, branding, sales, and marketing functions of the Company.
⮚ Mr. K. P. Unnikrishnan is the Assistant Vice President – New Product Development of the Company. He has a multi-functional experience of 36 years
⮚ Mr. Sabrinath Gopalkrishnan Nair is the Senior Manager – Purchase of the Company. He has experience of over 28 years in accounts, inventory control and logistics operations.
⮚ Consistently growing company with established brand presence
⮚ Wide Product Portfolio and Multiple SKUs
⮚ Focusing on multiple end-user industries
⮚ Extensive distribution network across India catering to customers.
⮚ Efficient manufacturing set-up with scope for expansion
⮚ Effective quality checks
⮚ R&D set up for constant product improvement and new product development
⮚ Further, strengthen brand image
⮚ Expansion of manufacturing facility
⮚ Further expansion of distribution network across India and globally
⮚ The impact of the COVID-19 pandemic on business and operations is uncertain.
⮚ The company does not have any long-term arrangements with its distributors.
⮚ Restrictions on the import of raw materials may adversely impact the business.
⮚ Prices of the principal raw materials are subject to changes in the prices of crude oil.
⮚ The company has incurred losses in the recent past.
HP ADHESIVES LIMITED
COMPARISON WITH LISTED INDUSTRY PEERS (AS OF 31ST MARCH 2021)
Name of the Company EPS (Basic) NAV P/E Total Income (Mn) RoNW (%)HP Adhesives Limited 7.74 9.74 35 118.16 79%Peer GroupPidilite Industries Limited 22.26 114.78 81.28 7293.00 114.78
FINANCIALS (RESTATED CONSOLIDATED)
Particulars (Rs. In Lakh) FY 2021 FY 2020 FY 2019Equity Share Capital 1,300.00 1,300.00 1,300.00Other Equity (34.12) (1,051.56) 166.23Net Worth 1,265.88 248.44 1,466.23Total Borrowings 3,138.52 3,405.98 2,358.33Revenue from Operations 11,816.16 9,547.93 8,741.75EBITDA 1,768.67 691.95 870.09Profit Before Tax 1,323.02 (536.06) 405.91Net Profit for the year 1,005.96 (467.05) 400.07
Rating SUBSCRIBE Issue Offer Issue Opens on Dec 13, 2021Issue Close on Dec 15, 2021Total IPO size (cr) 1,398.30Fresh issue (cr) 600.00Offer For Sale (cr) 798.30Price Band (INR) 780-796Market Lot 18Face Value (INR) 2Retail Allocation 35%Listing On NSE, BSE
Objects of the issue
⮚ For funding working capital requirement of the subsidiary.
⮚ For general corporate purposes. Issue Break-up (%)QIB Portion 50NIB Portion 15Retail Portion
⮚ Shareholding (No. of Shares)Pre Issue 111,761,165Post Issue 119,305,676
Indicative Timetable
Finalisation of Basis of Allotment 20-12-2021Refunds/Unblocking ASBA Fund 21-12-2021Credit of equity shares to DP A/c 22-12-2021Trading commences 23-12-2021
Incorporated in 2006, Medplus Health Services is India's second-largest pharmacy retailer in terms of the number of stores and revenue.
The company offers pharmaceutical and wellness products i.e. medicines, vitamins, medical devices, test kits, and fast-moving consumer goods i.e. home and personal care products, baby care products, sanitisers, soaps, and detergents, etc.
It is also the first pharmacy retailer in India to offer an omnichannel platform wherein customers can purchase products through stores, place orders over the telephone, online orders, and a Click and Pick facility.
⮚ According to the Technopak Report, it is India's first pharmaceutical retailer to offer an omnichannel platform. This approach aims to broaden and expand the Company's client base while also enhancing "convenience" as a primary customer value proposition and retaining customers inside its ecosystem.
⮚ As of September 30, 2021, we operated 546 stores in Karnataka, 475 stores in Tamil Nadu, 474 stores in Telangana, 297 stores in Andhra Pradesh, 224 stores in West Bengal, 221 stores in Maharashtra and 89 stores in Odisha.
⮚ The company has an established track record of delivering strong financial performance. Between the financial year 2019 and financial year 2021, total revenue from operations grew at a compound annual growth rate (“CAGR”) of 16.21% from ₹22,727.37 million to ₹30,692.69 million.
⮚ The company’s business operations across the entire value chain are backward integrated and are wholly managed and operated by itself. The company's operations are supported by its technology-driven supply chain and distribution infrastructure, which is arranged in a hub-and-spoke model and gives it a strong foundation and substantial power to continue to grow.
Over the period of FY19 to FY21, company revenue increased from Rs 2,284.94 crore to Rs 3,090.81 crore, while profits grew from Rs 11.92 crore in FY19 to Rs 63.11 crore in FY21 with only a slight dip in FY20.
Margins of the company are increasing slowly.
The company is the second-largest pharmacy retailer in India which offers an omnichannel platform. After a dismal performance for FY20, the company posted super earnings recently.
The company has low margins, but it is expanding. We believe that there are growth opportunities in the industry and might perform better over the period. There are no listed peers and IPO is arriving at a PE of 71x to its annualized FY22 earnings.
Prima-facie the valuation looks expensive but over the period of time, we believe the company's growth may justify its valuation.
MEDPLUS HEALTH SERVICES LIMITED
⮚ Ganga Madhukar Reddy is the Managing Director and Chief Executive Officer of the Company. He is one of the Promoters of the Company and has been a Director of the Company since its incorporation on November 30, 2006. He holds a bachelor’s degree in medicine and surgery and a master’s degree in business administration.
⮚ Cherukupalli Bhaskar Reddy is the Chief Operating Officer – outlet operations of the company. He joined the company on March 1, 2007. He has over 14 years of experience in the pharmaceutical industry.
⮚ Surendranath Mantena is the Chief Operating Officer – MedPlus Mart of the company. He joined the company on October 1, 2010.
⮚ Hemanth Kundavaram is the CFO of the company. He joined the company on January 2, 2021. He has over 15 years of experience in corporate finance and accounting in various industries.
⮚ Parag Jain is the company secretary and compliance officer of the company. He joined the company on March 10, 2014. He has 14 years of experience as a company secretary.
⮚ Atul Gupta is the Non-Executive Director of the company. He has over 13 years of experience in the investment industry.
⮚ Murali Sivaraman is the Non-Executive Independent Director of the company. He was previously associated with Philips Lighting.
⮚ India’s Second Largest Pharmacy retailer Company.
⮚ Strong brand name and customer value proposition.
⮚ Successful Track Record of Expansion Using a Distinct Cluster-based and Replicable Store Unit Expansion Approach
⮚ High-Density Store Network Enhancing Omni-channel Proposition
⮚ Lean Cost Structure and Technology-Driven Operations
⮚ Well Qualified, Experienced and Entrepreneurial Board and Senior Management Team
⮚ Strong promoter background and an experienced and entrepreneurial management team
⮚ Strengthen the Market Position by Increasing Store Penetration in Existing Clusters and Developing New Cluster
⮚ Further Develop the Omni-channel Platform with a Hyper-local Delivery Model
⮚ Increase the Share of Private Labels and Enhance the Stock Keeping Unit (“SKU”) Mix
⮚ Continue to Increase Operating Efficiency and Enhance Supply Chain Management to Drive Profitability
⮚ Enhance Revenue and Increase Customer Wallet Share.
⮚ Changes in prescription medicine prices and commercial terms may have a negative impact on their business.
⮚ Their company, subsidiaries, promoters, and directors are involved in ongoing legal procedures.
⮚ Privacy and security rules govern the use and sharing of personally sensitive information, especially personal health information.
⮚ Their financial success may be harmed if they will not effectively manage inventory and forecast demand.
⮚ Any negative news or occurrence related to the Indian pharma industry may have a negative impact on their business.
MEDPLUS HEALTH SERVICES LIMITED
COMPARISON WITH LISTED INDUSTRY PEERS
There are no listed companies in India that engage in a business similar to that of the Company. Accordingly, it is not possible to provide an industry comparison in relation to the Company
FINANCIALS (RESTATED CONSOLIDATED)
Particulars (Rs. In Millions) FY 2021 FY 2020 FY 2019 Equity Share Capital 4.48 1.94 1.94Other Equity 7,301.05 5,276.08 2,911.43 Net Worth 7,305.53 5,278.02 2,913.37 Total Borrowings 1,352.35 1,050.51 1,044.02 Revenue from Operations 30,692.69 28,706.03 22,727.37 EBITDA 2,382.13 1,509.62 1,313.47 Profit Before Tax 950.98 293.59 227.51 Net Profit for the year 631.11 17.94 119.22
Trust Our Expert Picks
for Your Investments!
.webp)
.png)
.png)
